'The clinical trial death, described in an unpublished case report Science has obtained, is the second thought to be associated with the antibody called lecanemab. The newly disclosed fatality intensifies questions about its safety and how widely lecanemab should be prescribed if ultimately approved by regulators.'

https://www.science.org/content/article/second-death-linked-potential-antibody-treatment-alzheimer-s-disease